In a large cohort study of adult AML patients with DEK-NUP214, seven patients who had relapsed either after allo-HSCT or post-chemotherapy were treated with TKIs in isolation or in combination with chemotherapy, which failed to achieve a response in the majority of patients.[31] These findings suggest that novel treatment strategies are needed to improve patient outcomes. The gene discussed is NUP214; the disease is acute myeloid leukemia.